XML 52 R31.htm IDEA: XBRL DOCUMENT v3.19.3
Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Collaboration And Other Agreements [Line Items]          
Revenues $ 18,741 $ 20,798 $ 38,996 $ 44,327  
Deferred revenue, current 23,571   23,571   $ 21,721
Deferred revenue, net of current portion 10,037   10,037   $ 19,001
I-Mab | I-Mab Biopharma Collaboration and License Agreement          
Collaboration And Other Agreements [Line Items]          
Non-refundable upfront payment     15,000    
Potential development and regulatory milestone payments under agreement 135,000   135,000    
Estimated variable consideration     1,000    
Revenues 1,100   1,100    
Deferred revenue 14,400   14,400    
Deferred revenue, current 4,400   4,400    
Deferred revenue, net of current portion $ 10,000   $ 10,000